BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for patients with skin cancer. OBJECTIVES: This part of the EPIDERM (European Prevention Initiative for Dermatological Malignancies) project is aimed at the evaluation of the treatment preferences for skin cancer in eight countries of the European Union. METHODS: A multicentre hospital-based case-control study was carried out at dermatology departments in Finland, Germany, Greece, Italy, Malta, Poland, Scotland and Spain. Patients with skin cancer (basal cell carcinoma, actinic keratosis, squamous cell carcinoma, cutaneous malignant melanoma and Bowen disease) were consecutively enrolled between July 2008 and July 2010. Information on the study variables (sex, age, country, tumour type, anatomical location and treatment) was obtained from questionnaires designed by the EPIDERM project. RESULTS: In total, 1708 patients with skin cancer were included. Surgery was the first treatment option in 76·5% of the patients (P = 0·001). Actinic keratosis was the only tumour type in which nonsurgical treatment was more frequent than surgery (91·4%). Tumours on the head were less likely to be surgically excised than those at other locations (odds ratio 0·25, P = 0·001). Simple excision or curettage was the most common surgical procedure (65·4%), followed by graft and flaps (22·4%). Cryotherapy was the most common nonsurgical option (52·4%), followed by imiquimod (18·0%), photodynamic therapy (PDT; 12·0%), 5-fluorouracil (5-FU; 5·7%), and diclofenac with hyaluronic acid (4·0%). CONCLUSIONS: Surgery remains the first-choice treatment of skin cancer. Regarding nonsurgical treatments, the conservative treatments available (imiquimod, 5-FU, PDT and diclofenac gel) have not yet exceeded the use of ablative options such as cryotherapy despite their accepted benefit of treating field cancerization.

Assessing physicians' preferences on skin cancer treatment in Europe / Ferrandiz, L; Ruiz de Casas, A; Trakatelli, M; de Vries E, Ulrich; Aquilina, S; Saksela, O; Majewski, S; Ranki, A; Proby, C; Magnoni, Cristina; Pitkänen, S; Kalokasidis, K; Siskou, S; Hinrichs, B; Altsitsiadis, E; Stockfleth, E; Moreno Ramirez, D; Epiderm, Group. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 167:2(2012), pp. 29-35. [10.1111/j.1365-2133.2012.11084.x]

Assessing physicians' preferences on skin cancer treatment in Europe

MAGNONI, Cristina;
2012

Abstract

BACKGROUND: A wide variety of both surgical and nonsurgical therapies is currently available for patients with skin cancer. OBJECTIVES: This part of the EPIDERM (European Prevention Initiative for Dermatological Malignancies) project is aimed at the evaluation of the treatment preferences for skin cancer in eight countries of the European Union. METHODS: A multicentre hospital-based case-control study was carried out at dermatology departments in Finland, Germany, Greece, Italy, Malta, Poland, Scotland and Spain. Patients with skin cancer (basal cell carcinoma, actinic keratosis, squamous cell carcinoma, cutaneous malignant melanoma and Bowen disease) were consecutively enrolled between July 2008 and July 2010. Information on the study variables (sex, age, country, tumour type, anatomical location and treatment) was obtained from questionnaires designed by the EPIDERM project. RESULTS: In total, 1708 patients with skin cancer were included. Surgery was the first treatment option in 76·5% of the patients (P = 0·001). Actinic keratosis was the only tumour type in which nonsurgical treatment was more frequent than surgery (91·4%). Tumours on the head were less likely to be surgically excised than those at other locations (odds ratio 0·25, P = 0·001). Simple excision or curettage was the most common surgical procedure (65·4%), followed by graft and flaps (22·4%). Cryotherapy was the most common nonsurgical option (52·4%), followed by imiquimod (18·0%), photodynamic therapy (PDT; 12·0%), 5-fluorouracil (5-FU; 5·7%), and diclofenac with hyaluronic acid (4·0%). CONCLUSIONS: Surgery remains the first-choice treatment of skin cancer. Regarding nonsurgical treatments, the conservative treatments available (imiquimod, 5-FU, PDT and diclofenac gel) have not yet exceeded the use of ablative options such as cryotherapy despite their accepted benefit of treating field cancerization.
167
2
29
35
Assessing physicians' preferences on skin cancer treatment in Europe / Ferrandiz, L; Ruiz de Casas, A; Trakatelli, M; de Vries E, Ulrich; Aquilina, S; Saksela, O; Majewski, S; Ranki, A; Proby, C; Magnoni, Cristina; Pitkänen, S; Kalokasidis, K; Siskou, S; Hinrichs, B; Altsitsiadis, E; Stockfleth, E; Moreno Ramirez, D; Epiderm, Group. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 167:2(2012), pp. 29-35. [10.1111/j.1365-2133.2012.11084.x]
Ferrandiz, L; Ruiz de Casas, A; Trakatelli, M; de Vries E, Ulrich; Aquilina, S; Saksela, O; Majewski, S; Ranki, A; Proby, C; Magnoni, Cristina; Pitkänen, S; Kalokasidis, K; Siskou, S; Hinrichs, B; Altsitsiadis, E; Stockfleth, E; Moreno Ramirez, D; Epiderm, Group
File in questo prodotto:
File Dimensione Formato  
assessing.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 539.34 kB
Formato Adobe PDF
539.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1081328
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact